<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In <z:e sem="disease" ids="C0038505" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="PKWS">Sturge-Weber syndrome</z:e> choroidal <z:hpo ids='HP_0001028'>hemangiomas</z:hpo> occur in up to 55% </plain></SENT>
<SENT sid="1" pm="."><plain>With a few exceptions it is a diffuse <z:hpo ids='HP_0001028'>hemangioma</z:hpo> and it always affects the eye ipsilateral to the <z:hpo ids='HP_0003764'>naevus</z:hpo> flammeus </plain></SENT>
<SENT sid="2" pm="."><plain>To the best of our knowledge, a contralateral circumscribed choroidal <z:hpo ids='HP_0001028'>hemangioma</z:hpo> has not yet been described </plain></SENT>
<SENT sid="3" pm="."><plain>HISTORY AND CLINICAL FINDINGS: We present a 34-year-old male caucasian with a left-sided <z:hpo ids='HP_0003764'>naevus</z:hpo> flammeus and a right-sided circumscribed choroidal <z:hpo ids='HP_0001028'>hemangioma</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Ipsilateral to the <z:hpo ids='HP_0003764'>naevus</z:hpo>, the left eye showed typical vascular anomalies of the conjunctiva and episclera as well as in the anterior chamber angle with <z:mp ids='MP_0011481'>anterior synechia</z:mp> formation and circumscribed <z:hpo ids='HP_0001089'>iris atrophy</z:hpo> without secondary <z:hpo ids='HP_0000501'>glaucoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="46" ids="15035">Retinal</z:chebi> and choroidal vasculature was <z:mpath ids='MPATH_458'>normal</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>In the contralateral eye the anterior segment was <z:mpath ids='MPATH_458'>normal</z:mpath>, but there was a juxtafoveolar circumscribed choroidal <z:hpo ids='HP_0001028'>hemangioma</z:hpo> of about 7.5 x 4.5 mm along the superior temporal vascular arcade </plain></SENT>
<SENT sid="7" pm="."><plain>The <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was detected when vision dropped to 0.4 due to an exsudative <z:hpo ids='HP_0000541'>retinal detachment</z:hpo> over the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> involving the fovea </plain></SENT>
<SENT sid="8" pm="."><plain>THERAPY AND CLINICAL COURSE: Complete regression of the exsudative detachment occurred under oral <z:chebi fb="0" ids="27690">Acetazolamide</z:chebi> (1000 mg/d), but after dose reduction to 500 mg/d the exsudation recurred </plain></SENT>
<SENT sid="9" pm="."><plain>Thereafter, the surface of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> was treated with argongreen grid lasercoagulation in 3 sessions under <z:chebi fb="0" ids="27690">Acetazolamide</z:chebi> cover </plain></SENT>
<SENT sid="10" pm="."><plain>Following scar formation the retina has stayed completely attached even after discontinuation of oral <z:chebi fb="0" ids="27690">Acetazolamide</z:chebi> therapy with a follow-up of now 7 months </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Visual prognosis after exsudative macula detachment is depended on rapid <z:chebi fb="46" ids="15035">retinal</z:chebi> reattachment </plain></SENT>
<SENT sid="12" pm="."><plain>Therefore, early and effective treatment is mandatory </plain></SENT>
<SENT sid="13" pm="."><plain>Systemic application of Acetazolamid (1000 mg/d orally) led to a rapid reattachment of the retina with an excellent visual result </plain></SENT>
<SENT sid="14" pm="."><plain>However, dose-reduction was followed by an immediate recurrency </plain></SENT>
<SENT sid="15" pm="."><plain>We therefore suggest to perform an Argongreen grid lasercoagulation of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> surface while the patient is still under systemic Aceazolamid </plain></SENT>
<SENT sid="16" pm="."><plain>This strategy has proven successful in this case </plain></SENT>
</text></document>